Kyowa Kirin Co., Ltd.: Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA?(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)

CRYSVITA is the first approved biologic treatment in the EU for patients with TIO who cannot undergo surgical removal of tumours Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that

Related Keywords

Japan ,Kyowa ,Hokkaido ,Hamburg ,Germany ,Galashiels ,Scottish Borders ,The ,United Kingdom ,United States ,America ,Stacey Minton ,Asia Pacific ,Abdul Mullick ,Ralf Oheim ,Hiroki Nakamura ,Kyowa Kirin ,Journal Of The Endocrine Society ,Kyowa Kirin International ,University Medical Center Hamburg ,Nasdaq ,Kyowa Kirin Co Ltd ,Ultragenyx Pharmaceutical Inc ,Contacts For Kyowa Kirin Co Ltd ,European Commission ,Department Of Osteology ,International Kyowa Kirin ,Mineral Research ,Tissue International ,Union Register Of Medicinal Products For Human ,Contacts For Kyowa Kirin International ,Tumour Induced Osteomalacia ,X Linked Hypophosphataemia ,Professor Ralf Oheim ,University Medical Center ,Ultragenyx Pharmaceutical ,North America ,Kirin International ,Business Park ,Union Register ,Medicinal Products ,Last Accessed ,Calcified Tissue ,Tumor Induced Osteomalacia ,Reviews Disease ,Label Trial Assessing Burosumab Efficacy ,Kyowa Kirin Announce ,Kyowa Kirin Announces Approval ,Hypophosphatemic Rickets ,Pirin ,Eceives ,European ,Commission ,Approval ,Rysvita ,Burosumab ,Treatment ,Humour ,Induced ,Osteomalacia ,